Global Multiple Myeloma Drugs Market Growth 2025-2031

October 2025 | 95 pages | ID: GD795B3A0D95EN
LP Information

Abstracts

The global Multiple Myeloma Drugs market size is predicted to grow from US$ 966 million in 2025 to US$ 1404 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Multiple Myeloma Drugs Industry Forecast? looks at past sales and reviews total world Multiple Myeloma Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Multiple Myeloma Drugs sales for 2025 through 2031. With Multiple Myeloma Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multiple Myeloma Drugs industry.

This Insight Report provides a comprehensive analysis of the global Multiple Myeloma Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Multiple Myeloma Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Multiple Myeloma Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multiple Myeloma Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multiple Myeloma Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Multiple Myeloma Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Chemotherapy
• Corticosteroids
• Immunomodulators
• Monoclonal Antibodies
• Histone Deacetylase (HDAC) Inhibitors
• Proteasome Inhibitors
• Others

Segmentation by Application:

• Men
• Women

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Amgen
• Johnson & Johnson
• Celgene
• Takeda Pharmaceutical
• Novartis
• Daiichi Sankyo
• Merck
• AB Science
• Teva
• PharmaMar

Key Questions Addressed in this Report

What is the 10-year outlook for the global Multiple Myeloma Drugs market?
What factors are driving Multiple Myeloma Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Multiple Myeloma Drugs market opportunities vary by end market size?
How does Multiple Myeloma Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Multiple Myeloma Drugs Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Multiple Myeloma Drugs by Country/Region, 2020, 2024 & 2031
2.2 Multiple Myeloma Drugs Segment by Type
  2.2.1 Chemotherapy
  2.2.2 Corticosteroids
  2.2.3 Immunomodulators
  2.2.4 Monoclonal Antibodies
  2.2.5 Histone Deacetylase (HDAC) Inhibitors
  2.2.6 Proteasome Inhibitors
  2.2.7 Others
2.3 Multiple Myeloma Drugs Sales by Type
  2.3.1 Global Multiple Myeloma Drugs Sales Market Share by Type (2020-2025)
  2.3.2 Global Multiple Myeloma Drugs Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Multiple Myeloma Drugs Sale Price by Type (2020-2025)
2.4 Multiple Myeloma Drugs Segment by Application
  2.4.1 Men
  2.4.2 Women
2.5 Multiple Myeloma Drugs Sales by Application
  2.5.1 Global Multiple Myeloma Drugs Sale Market Share by Application (2020-2025)
  2.5.2 Global Multiple Myeloma Drugs Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Multiple Myeloma Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Multiple Myeloma Drugs Breakdown Data by Company
  3.1.1 Global Multiple Myeloma Drugs Annual Sales by Company (2020-2025)
  3.1.2 Global Multiple Myeloma Drugs Sales Market Share by Company (2020-2025)
3.2 Global Multiple Myeloma Drugs Annual Revenue by Company (2020-2025)
  3.2.1 Global Multiple Myeloma Drugs Revenue by Company (2020-2025)
  3.2.2 Global Multiple Myeloma Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Multiple Myeloma Drugs Sale Price by Company
3.4 Key Manufacturers Multiple Myeloma Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Multiple Myeloma Drugs Product Location Distribution
  3.4.2 Players Multiple Myeloma Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MULTIPLE MYELOMA DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Multiple Myeloma Drugs Market Size by Geographic Region (2020-2025)
  4.1.1 Global Multiple Myeloma Drugs Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Multiple Myeloma Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Multiple Myeloma Drugs Market Size by Country/Region (2020-2025)
  4.2.1 Global Multiple Myeloma Drugs Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Multiple Myeloma Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Multiple Myeloma Drugs Sales Growth
4.4 APAC Multiple Myeloma Drugs Sales Growth
4.5 Europe Multiple Myeloma Drugs Sales Growth
4.6 Middle East & Africa Multiple Myeloma Drugs Sales Growth

5 AMERICAS

5.1 Americas Multiple Myeloma Drugs Sales by Country
  5.1.1 Americas Multiple Myeloma Drugs Sales by Country (2020-2025)
  5.1.2 Americas Multiple Myeloma Drugs Revenue by Country (2020-2025)
5.2 Americas Multiple Myeloma Drugs Sales by Type (2020-2025)
5.3 Americas Multiple Myeloma Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Multiple Myeloma Drugs Sales by Region
  6.1.1 APAC Multiple Myeloma Drugs Sales by Region (2020-2025)
  6.1.2 APAC Multiple Myeloma Drugs Revenue by Region (2020-2025)
6.2 APAC Multiple Myeloma Drugs Sales by Type (2020-2025)
6.3 APAC Multiple Myeloma Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Multiple Myeloma Drugs by Country
  7.1.1 Europe Multiple Myeloma Drugs Sales by Country (2020-2025)
  7.1.2 Europe Multiple Myeloma Drugs Revenue by Country (2020-2025)
7.2 Europe Multiple Myeloma Drugs Sales by Type (2020-2025)
7.3 Europe Multiple Myeloma Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Multiple Myeloma Drugs by Country
  8.1.1 Middle East & Africa Multiple Myeloma Drugs Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Multiple Myeloma Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Multiple Myeloma Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multiple Myeloma Drugs
10.3 Manufacturing Process Analysis of Multiple Myeloma Drugs
10.4 Industry Chain Structure of Multiple Myeloma Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Multiple Myeloma Drugs Distributors
11.3 Multiple Myeloma Drugs Customer

12 WORLD FORECAST REVIEW FOR MULTIPLE MYELOMA DRUGS BY GEOGRAPHIC REGION

12.1 Global Multiple Myeloma Drugs Market Size Forecast by Region
  12.1.1 Global Multiple Myeloma Drugs Forecast by Region (2026-2031)
  12.1.2 Global Multiple Myeloma Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Multiple Myeloma Drugs Forecast by Type (2026-2031)
12.7 Global Multiple Myeloma Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Amgen
  13.1.1 Amgen Company Information
  13.1.2 Amgen Multiple Myeloma Drugs Product Portfolios and Specifications
  13.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Amgen Main Business Overview
  13.1.5 Amgen Latest Developments
13.2 Johnson & Johnson
  13.2.1 Johnson & Johnson Company Information
  13.2.2 Johnson & Johnson Multiple Myeloma Drugs Product Portfolios and Specifications
  13.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Johnson & Johnson Main Business Overview
  13.2.5 Johnson & Johnson Latest Developments
13.3 Celgene
  13.3.1 Celgene Company Information
  13.3.2 Celgene Multiple Myeloma Drugs Product Portfolios and Specifications
  13.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Celgene Main Business Overview
  13.3.5 Celgene Latest Developments
13.4 Takeda Pharmaceutical
  13.4.1 Takeda Pharmaceutical Company Information
  13.4.2 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolios and Specifications
  13.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Takeda Pharmaceutical Main Business Overview
  13.4.5 Takeda Pharmaceutical Latest Developments
13.5 Novartis
  13.5.1 Novartis Company Information
  13.5.2 Novartis Multiple Myeloma Drugs Product Portfolios and Specifications
  13.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Novartis Main Business Overview
  13.5.5 Novartis Latest Developments
13.6 Daiichi Sankyo
  13.6.1 Daiichi Sankyo Company Information
  13.6.2 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolios and Specifications
  13.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Daiichi Sankyo Main Business Overview
  13.6.5 Daiichi Sankyo Latest Developments
13.7 Merck
  13.7.1 Merck Company Information
  13.7.2 Merck Multiple Myeloma Drugs Product Portfolios and Specifications
  13.7.3 Merck Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Merck Main Business Overview
  13.7.5 Merck Latest Developments
13.8 AB Science
  13.8.1 AB Science Company Information
  13.8.2 AB Science Multiple Myeloma Drugs Product Portfolios and Specifications
  13.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 AB Science Main Business Overview
  13.8.5 AB Science Latest Developments
13.9 Teva
  13.9.1 Teva Company Information
  13.9.2 Teva Multiple Myeloma Drugs Product Portfolios and Specifications
  13.9.3 Teva Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Teva Main Business Overview
  13.9.5 Teva Latest Developments
13.10 PharmaMar
  13.10.1 PharmaMar Company Information
  13.10.2 PharmaMar Multiple Myeloma Drugs Product Portfolios and Specifications
  13.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 PharmaMar Main Business Overview
  13.10.5 PharmaMar Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Multiple Myeloma Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Multiple Myeloma Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Corticosteroids
Table 5. Major Players of Immunomodulators
Table 6. Major Players of Monoclonal Antibodies
Table 7. Major Players of Histone Deacetylase (HDAC) Inhibitors
Table 8. Major Players of Proteasome Inhibitors
Table 9. Major Players of Others
Table 10. Global Multiple Myeloma Drugs Sales by Type (2020-2025) & (K Units)
Table 11. Global Multiple Myeloma Drugs Sales Market Share by Type (2020-2025)
Table 12. Global Multiple Myeloma Drugs Revenue by Type (2020-2025) & ($ million)
Table 13. Global Multiple Myeloma Drugs Revenue Market Share by Type (2020-2025)
Table 14. Global Multiple Myeloma Drugs Sale Price by Type (2020-2025) & (USD/Unit)
Table 15. Global Multiple Myeloma Drugs Sale by Application (2020-2025) & (K Units)
Table 16. Global Multiple Myeloma Drugs Sale Market Share by Application (2020-2025)
Table 17. Global Multiple Myeloma Drugs Revenue by Application (2020-2025) & ($ million)
Table 18. Global Multiple Myeloma Drugs Revenue Market Share by Application (2020-2025)
Table 19. Global Multiple Myeloma Drugs Sale Price by Application (2020-2025) & (USD/Unit)
Table 20. Global Multiple Myeloma Drugs Sales by Company (2020-2025) & (K Units)
Table 21. Global Multiple Myeloma Drugs Sales Market Share by Company (2020-2025)
Table 22. Global Multiple Myeloma Drugs Revenue by Company (2020-2025) & ($ millions)
Table 23. Global Multiple Myeloma Drugs Revenue Market Share by Company (2020-2025)
Table 24. Global Multiple Myeloma Drugs Sale Price by Company (2020-2025) & (USD/Unit)
Table 25. Key Manufacturers Multiple Myeloma Drugs Producing Area Distribution and Sales Area
Table 26. Players Multiple Myeloma Drugs Products Offered
Table 27. Multiple Myeloma Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global Multiple Myeloma Drugs Sales by Geographic Region (2020-2025) & (K Units)
Table 31. Global Multiple Myeloma Drugs Sales Market Share Geographic Region (2020-2025)
Table 32. Global Multiple Myeloma Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 33. Global Multiple Myeloma Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 34. Global Multiple Myeloma Drugs Sales by Country/Region (2020-2025) & (K Units)
Table 35. Global Multiple Myeloma Drugs Sales Market Share by Country/Region (2020-2025)
Table 36. Global Multiple Myeloma Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 37. Global Multiple Myeloma Drugs Revenue Market Share by Country/Region (2020-2025)
Table 38. Americas Multiple Myeloma Drugs Sales by Country (2020-2025) & (K Units)
Table 39. Americas Multiple Myeloma Drugs Sales Market Share by Country (2020-2025)
Table 40. Americas Multiple Myeloma Drugs Revenue by Country (2020-2025) & ($ millions)
Table 41. Americas Multiple Myeloma Drugs Sales by Type (2020-2025) & (K Units)
Table 42. Americas Multiple Myeloma Drugs Sales by Application (2020-2025) & (K Units)
Table 43. APAC Multiple Myeloma Drugs Sales by Region (2020-2025) & (K Units)
Table 44. APAC Multiple Myeloma Drugs Sales Market Share by Region (2020-2025)
Table 45. APAC Multiple Myeloma Drugs Revenue by Region (2020-2025) & ($ millions)
Table 46. APAC Multiple Myeloma Drugs Sales by Type (2020-2025) & (K Units)
Table 47. APAC Multiple Myeloma Drugs Sales by Application (2020-2025) & (K Units)
Table 48. Europe Multiple Myeloma Drugs Sales by Country (2020-2025) & (K Units)
Table 49. Europe Multiple Myeloma Drugs Revenue by Country (2020-2025) & ($ millions)
Table 50. Europe Multiple Myeloma Drugs Sales by Type (2020-2025) & (K Units)
Table 51. Europe Multiple Myeloma Drugs Sales by Application (2020-2025) & (K Units)
Table 52. Middle East & Africa Multiple Myeloma Drugs Sales by Country (2020-2025) & (K Units)
Table 53. Middle East & Africa Multiple Myeloma Drugs Revenue Market Share by Country (2020-2025)
Table 54. Middle East & Africa Multiple Myeloma Drugs Sales by Type (2020-2025) & (K Units)
Table 55. Middle East & Africa Multiple Myeloma Drugs Sales by Application (2020-2025) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of Multiple Myeloma Drugs
Table 57. Key Market Challenges & Risks of Multiple Myeloma Drugs
Table 58. Key Industry Trends of Multiple Myeloma Drugs
Table 59. Multiple Myeloma Drugs Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. Multiple Myeloma Drugs Distributors List
Table 62. Multiple Myeloma Drugs Customer List
Table 63. Global Multiple Myeloma Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 64. Global Multiple Myeloma Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Americas Multiple Myeloma Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Americas Multiple Myeloma Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. APAC Multiple Myeloma Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 68. APAC Multiple Myeloma Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 69. Europe Multiple Myeloma Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 70. Europe Multiple Myeloma Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Middle East & Africa Multiple Myeloma Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 72. Middle East & Africa Multiple Myeloma Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 73. Global Multiple Myeloma Drugs Sales Forecast by Type (2026-2031) & (K Units)
Table 74. Global Multiple Myeloma Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 75. Global Multiple Myeloma Drugs Sales Forecast by Application (2026-2031) & (K Units)
Table 76. Global Multiple Myeloma Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 77. Amgen Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Multiple Myeloma Drugs Product Portfolios and Specifications
Table 79. Amgen Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Johnson & Johnson Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Johnson & Johnson Multiple Myeloma Drugs Product Portfolios and Specifications
Table 84. Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Johnson & Johnson Main Business
Table 86. Johnson & Johnson Latest Developments
Table 87. Celgene Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Celgene Multiple Myeloma Drugs Product Portfolios and Specifications
Table 89. Celgene Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. Celgene Main Business
Table 91. Celgene Latest Developments
Table 92. Takeda Pharmaceutical Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolios and Specifications
Table 94. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 95. Takeda Pharmaceutical Main Business
Table 96. Takeda Pharmaceutical Latest Developments
Table 97. Novartis Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Novartis Multiple Myeloma Drugs Product Portfolios and Specifications
Table 99. Novartis Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 100. Novartis Main Business
Table 101. Novartis Latest Developments
Table 102. Daiichi Sankyo Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Daiichi Sankyo Multiple Myeloma Drugs Product Portfolios and Specifications
Table 104. Daiichi Sankyo Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 105. Daiichi Sankyo Main Business
Table 106. Daiichi Sankyo Latest Developments
Table 107. Merck Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Merck Multiple Myeloma Drugs Product Portfolios and Specifications
Table 109. Merck Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 110. Merck Main Business
Table 111. Merck Latest Developments
Table 112. AB Science Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. AB Science Multiple Myeloma Drugs Product Portfolios and Specifications
Table 114. AB Science Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 115. AB Science Main Business
Table 116. AB Science Latest Developments
Table 117. Teva Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Teva Multiple Myeloma Drugs Product Portfolios and Specifications
Table 119. Teva Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 120. Teva Main Business
Table 121. Teva Latest Developments
Table 122. PharmaMar Basic Information, Multiple Myeloma Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. PharmaMar Multiple Myeloma Drugs Product Portfolios and Specifications
Table 124. PharmaMar Multiple Myeloma Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 125. PharmaMar Main Business
Table 126. PharmaMar Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Multiple Myeloma Drugs
Figure 2. Multiple Myeloma Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multiple Myeloma Drugs Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Multiple Myeloma Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Multiple Myeloma Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Multiple Myeloma Drugs Sales Market Share by Country/Region (2024)
Figure 10. Multiple Myeloma Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Chemotherapy
Figure 12. Product Picture of Corticosteroids
Figure 13. Product Picture of Immunomodulators
Figure 14. Product Picture of Monoclonal Antibodies
Figure 15. Product Picture of Histone Deacetylase (HDAC) Inhibitors
Figure 16. Product Picture of Proteasome Inhibitors
Figure 17. Product Picture of Others
Figure 18. Global Multiple Myeloma Drugs Sales Market Share by Type in 2025
Figure 19. Global Multiple Myeloma Drugs Revenue Market Share by Type (2020-2025)
Figure 20. Multiple Myeloma Drugs Consumed in Men
Figure 21. Global Multiple Myeloma Drugs Market: Men (2020-2025) & (K Units)
Figure 22. Multiple Myeloma Drugs Consumed in Women
Figure 23. Global Multiple Myeloma Drugs Market: Women (2020-2025) & (K Units)
Figure 24. Global Multiple Myeloma Drugs Sale Market Share by Application (2024)
Figure 25. Global Multiple Myeloma Drugs Revenue Market Share by Application in 2025
Figure 26. Multiple Myeloma Drugs Sales by Company in 2025 (K Units)
Figure 27. Global Multiple Myeloma Drugs Sales Market Share by Company in 2025
Figure 28. Multiple Myeloma Drugs Revenue by Company in 2025 ($ millions)
Figure 29. Global Multiple Myeloma Drugs Revenue Market Share by Company in 2025
Figure 30. Global Multiple Myeloma Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Multiple Myeloma Drugs Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Multiple Myeloma Drugs Sales 2020-2025 (K Units)
Figure 33. Americas Multiple Myeloma Drugs Revenue 2020-2025 ($ millions)
Figure 34. APAC Multiple Myeloma Drugs Sales 2020-2025 (K Units)
Figure 35. APAC Multiple Myeloma Drugs Revenue 2020-2025 ($ millions)
Figure 36. Europe Multiple Myeloma Drugs Sales 2020-2025 (K Units)
Figure 37. Europe Multiple Myeloma Drugs Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Multiple Myeloma Drugs Sales 2020-2025 (K Units)
Figure 39. Middle East & Africa Multiple Myeloma Drugs Revenue 2020-2025 ($ millions)
Figure 40. Americas Multiple Myeloma Drugs Sales Market Share by Country in 2025
Figure 41. Americas Multiple Myeloma Drugs Revenue Market Share by Country (2020-2025)
Figure 42. Americas Multiple Myeloma Drugs Sales Market Share by Type (2020-2025)
Figure 43. Americas Multiple Myeloma Drugs Sales Market Share by Application (2020-2025)
Figure 44. United States Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Multiple Myeloma Drugs Sales Market Share by Region in 2025
Figure 49. APAC Multiple Myeloma Drugs Revenue Market Share by Region (2020-2025)
Figure 50. APAC Multiple Myeloma Drugs Sales Market Share by Type (2020-2025)
Figure 51. APAC Multiple Myeloma Drugs Sales Market Share by Application (2020-2025)
Figure 52. China Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. India Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Multiple Myeloma Drugs Sales Market Share by Country in 2025
Figure 60. Europe Multiple Myeloma Drugs Revenue Market Share by Country (2020-2025)
Figure 61. Europe Multiple Myeloma Drugs Sales Market Share by Type (2020-2025)
Figure 62. Europe Multiple Myeloma Drugs Sales Market Share by Application (2020-2025)
Figure 63. Germany Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. France Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Application (2020-2025)
Figure 71. Egypt Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Multiple Myeloma Drugs Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Multiple Myeloma Drugs in 2025
Figure 77. Manufacturing Process Analysis of Multiple Myeloma Drugs
Figure 78. Industry Chain Structure of Multiple Myeloma Drugs
Figure 79. Channels of Distribution
Figure 80. Global Multiple Myeloma Drugs Sales Market Forecast by Region (2026-2031)
Figure 81. Global Multiple Myeloma Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Multiple Myeloma Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Multiple Myeloma Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Multiple Myeloma Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Multiple Myeloma Drugs Revenue Market Share Forecast by Application (2026-2031)